


## IN THE CLAIMS

Please amend the claims as follows:

Claims 1-81: Canceled.

82. (Currently Amended) A compound represented by formula (I):




wherein

X is hydrogen, halogen, trifluoromethyl, lower alkyl, unsubstituted or substituted phenyl, lower alkyl-thio, phenyl-lower alkyl-thio, lower alkyl-sulfonyl, or phenyl-lower alkyl-sulfonyl;



Y is hydrogen, hydroxyl, mercapto, lower alkoxy, lower alkyl-thio, halogen, lower alkyl, unsubstituted or substituted mononuclear aryl, or -N(R<sup>2</sup>)<sub>2</sub>;

R<sup>1</sup> is hydrogen or lower alkyl;

each R<sup>2</sup> is, independently, -R<sup>7</sup>, -(CH<sub>2</sub>)<sub>m</sub>-OR<sup>8</sup>, -(CH<sub>2</sub>)<sub>m</sub>-NR<sup>7</sup>R<sup>10</sup>, -(CH<sub>2</sub>)<sub>n</sub>(CHOR<sup>8</sup>)(CHOR<sup>8</sup>)<sub>n</sub>-CH<sub>2</sub>OR<sup>8</sup>, -(CH<sub>2</sub>CH<sub>2</sub>O)<sub>m</sub>-R<sup>8</sup>, -(CH<sub>2</sub>CH<sub>2</sub>O)<sub>m</sub>-CH<sub>2</sub>CH<sub>2</sub>NR<sup>7</sup>R<sup>10</sup>, -(CH<sub>2</sub>)<sub>n</sub>-C(=O)NR<sup>7</sup>R<sup>10</sup>, -(CH<sub>2</sub>)<sub>n</sub>-Z<sub>g</sub>-R<sup>7</sup>, -(CH<sub>2</sub>)<sub>m</sub>-NR<sup>10</sup>-CH<sub>2</sub>(CHOR<sup>8</sup>)(CHOR<sup>8</sup>)<sub>n</sub>-CH<sub>2</sub>OR<sup>8</sup>, -(CH<sub>2</sub>)<sub>n</sub>-CO<sub>2</sub>R<sup>7</sup>, or




$R^3$  and  $R^4$  are each, independently, hydrogen, a group represented by formula (A), lower alkyl, hydroxy lower alkyl, phenyl, phenyl-lower alkyl, (halophenyl)-lower alkyl, lower-(alkylphenylalkyl), lower alkoxyphenyl)-lower alkyl, naphthyl-lower alkyl, or pyridyl-lower alkyl, with the proviso that at least one of  $R^3$  and  $R^4$  is a group represented by formula (A):



wherein

each  $R^{\text{L}}$  is, independently,  $-\text{R}^7$ ,  $-(\text{CH}_2)_n\text{---OR}^8$ ,  $-\text{O}-(\text{CH}_2)_m\text{---OR}^8$ ,  $-(\text{CH}_2)_n\text{---NR}^7\text{R}^{10}$ ,  $-\text{O}-(\text{CH}_2)_m\text{---NR}^7\text{R}^{10}$ ,  $-(\text{CH}_2)_n(\text{CHOR}^8)(\text{CHOR}^8)_n\text{---CH}_2\text{OR}^8$ ,  $-\text{O}-(\text{CH}_2)_m(\text{CHOR}^8)(\text{CHOR}^8)_n\text{---CH}_2\text{OR}^8$ ,  $-(\text{CH}_2\text{CH}_2\text{O})_m\text{---R}^8$ ,  $-\text{O}-(\text{CH}_2\text{CH}_2\text{O})_m\text{---R}^8$ ,  $-(\text{CH}_2\text{CH}_2\text{O})_m\text{---CH}_2\text{CH}_2\text{NR}^7\text{R}^{10}$ ,  $-\text{O}-(\text{CH}_2\text{CH}_2\text{O})_m\text{---CH}_2\text{CH}_2\text{NR}^7\text{R}^{10}$ ,  $-(\text{CH}_2)_n\text{---C(=O)NR}^7\text{R}^{10}$ ,  $-\text{O}-(\text{CH}_2)_m\text{---C(=O)NR}^7\text{R}^{10}$ ,  $-(\text{CH}_2)_n\text{---(Z)}_g\text{---R}^7$ ,  $-\text{O}-(\text{CH}_2)_m\text{---(Z)}_g\text{---R}^7$ ,  $-(\text{CH}_2)_n\text{---NR}^{10}\text{---CH}_2(\text{CHOR}^8)(\text{CHOR}^8)_n\text{---CH}_2\text{OR}^8$ ,  $-\text{O}-(\text{CH}_2)_m\text{---NR}^{10}\text{---CH}_2(\text{CHOR}^8)(\text{CHOR}^8)_n\text{---CH}_2\text{OR}^8$ ,

$-(\text{CH}_2)_n\text{-CO}_2\text{R}^7$ ,  $-\text{O}-(\text{CH}_2)_m\text{-CO}_2\text{R}^7$ ,  $-\text{OSO}_3\text{H}$ ,  $-\text{O-glucuronide}$ ,  $-\text{O-glucose}$ , or



each x is, independently, O,  $\text{NR}^7$ , C=O, CHOH, C=N- $\text{R}^6$ , or represents a single bond;

each o is, independently, an integer from 0 to 10;

each p is, independently, an integer from 0 to 10;

with the proviso that (a) the sum of o and p in each contiguous chain is

from 1 to 10 when x is O,  $\text{NR}^7$ , C=O, or C=N- $\text{R}^6$  or (b) that the sum of o and p in each contiguous chain is from 4 to 10 when x represents a single bond;

each  $\text{R}^6$  is, independently,  $-\text{R}^7$ ,  $-\text{OH}$ ,  $-\text{OR}^{11}$ ,  $-\text{N}(\text{R}^7)_2$ ,  $-(\text{CH}_2)_m\text{-OR}^8$ ,

$-\text{O}-(\text{CH}_2)_m\text{-OR}^8$ ,  $-(\text{CH}_2)_n\text{-NR}^7\text{R}^{10}$ ,  $-\text{O}-(\text{CH}_2)_m\text{-NR}^7\text{R}^{10}$ ,

$-(\text{CH}_2)_n(\text{CHOR}^8)(\text{CHOR}^8)_n\text{-CH}_2\text{OR}^8$ ,  $-\text{O}-(\text{CH}_2)_m(\text{CHOR}^8)(\text{CHOR}^8)_n\text{-CH}_2\text{OR}^8$ ,

$-(\text{CH}_2\text{CH}_2\text{O})_m\text{-R}^8$ ,  $-\text{O}-(\text{CH}_2\text{CH}_2\text{O})_m\text{-R}^8$ ,  $-(\text{CH}_2\text{CH}_2\text{O})_m\text{-CH}_2\text{CH}_2\text{NR}^7\text{R}^{10}$ ,


$-\text{O}-(\text{CH}_2\text{CH}_2\text{O})_m\text{-CH}_2\text{CH}_2\text{NR}^7\text{R}^{10}$ ,  $-(\text{CH}_2)_n\text{-C(=O)NR}^7\text{R}^{10}$ ,

$-\text{O}-(\text{CH}_2)_m\text{-C(=O)NR}^7\text{R}^{10}$ ,  $-(\text{CH}_2)_n\text{-(Z)}_g\text{-R}^7$ ,  $-\text{O}-(\text{CH}_2)_m\text{-(Z)}_g\text{-R}^7$ ,

$-(\text{CH}_2)_n\text{-NR}^{10}\text{-CH}_2(\text{CHOR}^8)(\text{CHOR}^8)_n\text{-CH}_2\text{OR}^8$ ,

$-\text{O}-(\text{CH}_2)_m\text{-NR}^{10}\text{-CH}_2(\text{CHOR}^8)(\text{CHOR}^8)_n\text{-CH}_2\text{OR}^8$ ,


$-(\text{CH}_2)_n\text{-CO}_2\text{R}^7$ ,  $-\text{O}-(\text{CH}_2)_m\text{-CO}_2\text{R}^7$ ,  $-\text{OSO}_3\text{H}$ ,  $-\text{O-glucuronide}$ ,  $-\text{O-glucose}$ ,



wherein when two  $R^6$  are  $-OR^{11}$  and are located adjacent to each other on a phenyl ring, the alkyl moieties of the two  $R^6$  may be bonded together to form a methylenedioxy group;

each  $R^7$  is, independently, hydrogen or lower alkyl;

each  $R^8$  is, independently, hydrogen, lower alkyl,  $-C(=O)-R^{11}$ , glucuronide, 2-tetrahydropyranyl, or



each  $R^9$  is, independently,  $-CO_2R^7$ ,  $-CON(R^7)_2$ ,  $-SO_2CH_3$ , or  $-C(=O)R^7$ ;

each  $R^{10}$  is, independently,  $-H$ ,  $-SO_2CH_3$ ,  $-CO_2R^7$ ,  $-C(=O)NR^7R^9$ ,  $-C(=O)R^7$ , or  $-CH_2-(CHOH)_n-CH_2OH$ ;

each  $Z$  is, independently,  $CHOH$ ,  $C(=O)$ ,  $CHNR^7R^{10}$ ,  $C=NR^{10}$ , or  $NR^{10}$ ;

each  $R^{11}$  is, independently, lower alkyl;

each  $g$  is, independently, an integer from 1 to 6;

each  $m$  is, independently, an integer from 1 to 7;

each  $n$  is, independently, an integer from 0 to 7;

each  $Q$  is, independently,  $\text{C}-R^5$ ,  $\text{C}-R^6$ , or a nitrogen atom, wherein three  $Q$  in a ring are nitrogen atoms;

or a pharmaceutically acceptable salt thereof, and

inclusive of all enantiomers, diastereomers, and racemic mixtures thereof.

83. (Previously Presented) The compound of Claim 82, wherein  $Y$  is  $-NH_2$ .

84. (Previously Presented) The compound of Claim 83, wherein  $R^2$  is hydrogen.

85. (Previously Presented) The compound of Claim 84, wherein  $R^1$  is hydrogen.

86. (Previously Presented) The compound of Claim 85, wherein X is chlorine.

87. (Previously Presented) The compound of Claim 86, wherein  $R^3$  is hydrogen.

88. (Previously Presented) The compound of Claim 87, wherein each  $R^L$  is hydrogen.

89. (Previously Presented) The compound of Claim 88, wherein o is 4.

90. (Previously Presented) The compound of Claim 89, wherein p is 0.

91. (Previously Presented) The compound of Claim 90, wherein x represents a single bond.

92. (Previously Presented) The compound of Claim 91, wherein each  $R^6$  is hydrogen.

93. (Previously Presented) The compound of Claim 92, wherein

X is halogen;

Y is  $-N(R^7)_2$ ;

$R^1$  is hydrogen or  $C_1-C_3$  alkyl;

$R^2$  is  $-R^7$ ,  $-(CH_2)_m-OR^7$ , or  $-(CH_2)_n-CO_2R^7$ ;  $R^3$  is a group represented by formula (A); and

$R^4$  is hydrogen, a group represented by formula (A), or lower alkyl.

94. (Previously Presented) The compound of Claim 93, wherein

X is chloro or bromo;

Y is  $-N(R^7)_2$ ;

$R^2$  is hydrogen or  $C_1-C_3$  alkyl;

at most three  $R^6$  are other than hydrogen as defined above; and

at most three  $R^L$  are other than hydrogen as defined above.

95. (Previously Presented) The compound of Claim 94, wherein Y is  $-NH_2$ .

96. (Previously Presented) The compound of Claim 95, wherein

$R^4$  is hydrogen;

at most one  $R^L$  is other than hydrogen as defined above; and

at most two  $R^6$  are other than hydrogen as defined above.

97. (Previously Presented) The compound of Claim 96, wherein x is O,  $NR^7$ ,  $C=O$ ,  $CHOH$ , or  $C=N-R^6$ .

98. (Previously Presented) The compound of Claim 96, wherein x represents a single bond.

99. (Previously Presented) The compound of Claim 82, wherein x is O,  $\text{NR}^7$ ,  $\text{C}=\text{O}$ ,  $\text{CHOH}$ , or  $\text{C}=\text{N}-\text{R}^6$ .

100. (Previously Presented) The compound of Claim 82, wherein x represents a single bond.

101. (Previously Presented) The compound of Claim 82, wherein each  $\text{R}^6$  is hydrogen.

102. (Previously Presented) The compound of Claim 82, wherein at most two  $\text{R}^6$  are other than hydrogen as defined in Claim 82.

103. (Previously Presented) The compound of Claim 82, wherein one  $\text{R}^6$  is other than hydrogen as defined in Claim 82.

104. (Previously Presented) The compound of Claim 82, wherein one  $\text{R}^6$  is  $-\text{OH}$ .

105. (Previously Presented) The compound of Claim 82, wherein each  $\text{R}^L$  is hydrogen.

106. (Previously Presented) The compound of Claim 82, wherein at most two  $\text{R}^L$  are other than hydrogen as defined in Claim 82.

107. (Previously Presented) The compound of Claim 82, wherein one  $\text{R}^L$  is other than hydrogen as defined in Claim 82.

108. (Previously Presented) The compound of Claim 82, wherein x represents a single bond and the sum of o and p is 4 to 6.

109. (Previously Presented) The compound of Claim 82, which is in the form of a pharmaceutically acceptable salt.

110. (Previously Presented) The compound of Claim 82, which is in the form of a hydrochloride salt.

111. (Previously Presented) The compound of Claim 82, which is in the form of a mesylate salt.

112. (Previously Presented) A pharmaceutical composition, comprising the compound of Claim 82 and a pharmaceutically acceptable carrier.

113. (Currently Amended) A composition, comprising:  
the compound of Claim 82; and  
a P2Y2 receptor agonist inhibitor.

114. (Previously Presented) A composition, comprising:  
the compound of Claim 82; and  
a bronchodilator.

115. (Previously Presented) A method of blocking sodium channels, comprising contacting sodium channels with an effective amount of the compound of Claim 82.